# A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

> **NCT00175825** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 210 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **OTHER:** Placebo
- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT00175825
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-07
- **Primary completion:** 2006-06-29
- **Final completion:** 2006-06-29
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00175825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00175825, "A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00175825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*